大尺度应承担的合成

Frank Gupton
{"title":"大尺度应承担的合成","authors":"Frank Gupton","doi":"10.1002/0471266949.BMC032.PUB2","DOIUrl":null,"url":null,"abstract":"The capability to fulfill drug substance requirements to support the various elements of pharmaceutical development is an essential component of the overall drug development process. The preparation of bulk materials for toxicology, formulation development, and clinical supplies can represent a significant challenge, depending on such factors as the molecular complexity of the drug candidate, the quantities of materials required, and the state of development of the synthetic process. As a drug candidate proceeds through the various stages of drug development and into commercial launch, the challenge of process development is to ensure the uninterrupted supply of drug substance without compromising the ability to ultimately supply a commercially viable chemical process. This chapter provides a general overview of the issues and requirements associated with the development and scale-up of chemical processes for bulk active drug substances. An account of the nevirapine process development efforts at Boehringer Ingelheim is also provided as an example of the evolution of a chemical process from the initial efforts in medicinal chemistry to commercial-scale operations. \n \n \nKeywords: \n \nactive pharmaceutical ingredients; \ndrug development process; \nin-process controls; \nprocess chemist; \nprocess development","PeriodicalId":9514,"journal":{"name":"Burger's Medicinal Chemistry and Drug Discovery","volume":"1 1","pages":"1-24"},"PeriodicalIF":0.0000,"publicationDate":"2010-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"19","resultStr":"{\"title\":\"Large‐Scale Synthesis\",\"authors\":\"Frank Gupton\",\"doi\":\"10.1002/0471266949.BMC032.PUB2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The capability to fulfill drug substance requirements to support the various elements of pharmaceutical development is an essential component of the overall drug development process. The preparation of bulk materials for toxicology, formulation development, and clinical supplies can represent a significant challenge, depending on such factors as the molecular complexity of the drug candidate, the quantities of materials required, and the state of development of the synthetic process. As a drug candidate proceeds through the various stages of drug development and into commercial launch, the challenge of process development is to ensure the uninterrupted supply of drug substance without compromising the ability to ultimately supply a commercially viable chemical process. This chapter provides a general overview of the issues and requirements associated with the development and scale-up of chemical processes for bulk active drug substances. An account of the nevirapine process development efforts at Boehringer Ingelheim is also provided as an example of the evolution of a chemical process from the initial efforts in medicinal chemistry to commercial-scale operations. \\n \\n \\nKeywords: \\n \\nactive pharmaceutical ingredients; \\ndrug development process; \\nin-process controls; \\nprocess chemist; \\nprocess development\",\"PeriodicalId\":9514,\"journal\":{\"name\":\"Burger's Medicinal Chemistry and Drug Discovery\",\"volume\":\"1 1\",\"pages\":\"1-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-09-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"19\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Burger's Medicinal Chemistry and Drug Discovery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/0471266949.BMC032.PUB2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Burger's Medicinal Chemistry and Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/0471266949.BMC032.PUB2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 19

摘要

满足原料药需求以支持药物开发的各种要素的能力是整个药物开发过程的重要组成部分。根据候选药物的分子复杂性、所需材料的数量和合成过程的发展状况等因素,用于毒理学、配方开发和临床供应的散装材料的制备可能是一项重大挑战。当候选药物经过药物开发的各个阶段并进入商业上市时,工艺开发的挑战是确保原料药的不间断供应,而不影响最终提供商业上可行的化学工艺的能力。本章提供了与原料药化学工艺开发和扩大规模相关的问题和要求的总体概述。本文还提供了勃林格殷格翰奈韦拉平工艺开发工作的说明,作为化学工艺从最初的药物化学努力发展到商业规模操作的一个例子。关键词:活性药物成分;药物开发过程;进程内的控件;过程化学家;过程开发
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Large‐Scale Synthesis
The capability to fulfill drug substance requirements to support the various elements of pharmaceutical development is an essential component of the overall drug development process. The preparation of bulk materials for toxicology, formulation development, and clinical supplies can represent a significant challenge, depending on such factors as the molecular complexity of the drug candidate, the quantities of materials required, and the state of development of the synthetic process. As a drug candidate proceeds through the various stages of drug development and into commercial launch, the challenge of process development is to ensure the uninterrupted supply of drug substance without compromising the ability to ultimately supply a commercially viable chemical process. This chapter provides a general overview of the issues and requirements associated with the development and scale-up of chemical processes for bulk active drug substances. An account of the nevirapine process development efforts at Boehringer Ingelheim is also provided as an example of the evolution of a chemical process from the initial efforts in medicinal chemistry to commercial-scale operations. Keywords: active pharmaceutical ingredients; drug development process; in-process controls; process chemist; process development
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信